COR
vs
S&P 500
Over the past 12 months, COR has underperformed S&P 500, delivering a return of 10% compared to the S&P 500's 24% growth.
Stocks Performance
COR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
Mckesson Corp
NYSE:MCK
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Performance Gap
COR vs S&P 500
US |
Mckesson Corp
NYSE:MCK
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Performance By Year
COR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
Mckesson Corp
NYSE:MCK
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Competitors Performance
Cencora Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Cencora Inc
Glance View
Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.